Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)

[1]  W. Tang.  Faculty Opinions recommendation of Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  J. Moon,et al.  Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis , 2020, Journal of the American College of Cardiology.

[3]  M. Maurer,et al.  Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association , 2020, Circulation.

[4]  W. Saliba,et al.  Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis. , 2020, The American journal of cardiology.

[5]  C. Rapezzi,et al.  Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. , 2020, European heart journal cardiovascular Imaging.

[6]  A. Masri,et al.  Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy , 2020, European heart journal.

[7]  Sanjiv J. Shah,et al.  Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy , 2020, Circulation.

[8]  A. Hüsing-Kabar,et al.  Regression of cardiac amyloid load documented by cardiovascular magnetic resonance in a patient with hereditary amyloidosis , 2020, Clinical Research in Cardiology.

[9]  Hyun-Jai Cho,et al.  Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis. , 2020, Journal of the American College of Cardiology.

[10]  C. Morbach,et al.  Amyloidosis in Heart Failure , 2019, Current Heart Failure Reports.

[11]  M. Link,et al.  2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. , 2019, Heart rhythm.

[12]  F. Stellacci,et al.  Unraveling the complexity of amyloid polymorphism using gold nanoparticles and cryo-EM , 2019, Proceedings of the National Academy of Sciences.

[13]  Sanjiv J. Shah,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging , 2019, Journal of Nuclear Cardiology.

[14]  Sanjiv J. Shah,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI EXPERT CONSENSUS RECOMMENDATIONS FOR MULTIMODALITY IMAGING IN CARDIAC AMYLOIDOSIS: PART 1 OF 2-EVIDENCE BASE AND STANDARDIZED METHODS OF IMAGING. , 2019, Journal of cardiac failure.

[15]  C. Rapezzi,et al.  Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression , 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[16]  M. Maurer,et al.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[17]  F. Dominici,et al.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. , 2019, Circulation. Heart failure.

[18]  A. Yilmaz.  The "Native T1 Versus Extracellular Volume Fraction Paradox" in Cardiac Amyloidosis: Answer to the Million-Dollar Question? , 2019, JACC. Cardiovascular imaging.

[19]  P. Kellman,et al.  Native T1 and Extracellular Volume in Transthyretin Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[20]  P. Rainer,et al.  Unfolding Cardiac Amyloidosis - From Pathophysiology to Cure. , 2019, Current medicinal chemistry.

[21]  M. Kürtüncü,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2019, Turkish Journal Of Neurology.

[22]  James A. White,et al.  Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. , 2019, Journal of cardiac failure.

[23]  M. Rienstra,et al.  Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis , 2019, European heart journal.

[24]  M. Katsuno,et al.  Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights , 2019, Biomedicines.

[25]  R. Falk,et al.  State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis , 2018, Journal of Nuclear Cardiology.

[26]  S. Solomon,et al.  Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study , 2019, Circulation.

[27]  A. Benner,et al.  Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia , 2019, Haematologica.

[28]  M. Gertz,et al.  Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis , 2019, Acta Haematologica.

[29]  Amit R. Patel,et al.  A histopathologic schema to quantify the burden of cardiac amyloidosis: Relationship with survival and echocardiographic parameters , 2018, Echocardiography.

[30]  C. Izumi,et al.  Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy , 2018, ESC heart failure.

[31]  Michael J Ackerman,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2018, Journal of the American College of Cardiology.

[32]  Λίλιαν Μάντζιαρη,et al.  2018 ESC Guidelines for the diagnosis and management of syncope. , 2018, Revista espanola de cardiologia.

[33]  M. Maurer,et al.  Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types , 2018, Current opinion in cardiology.

[34]  M. Gertz.  Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment , 2018, American journal of hematology.

[35]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[36]  C. Varga,et al.  High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review , 2018, Bone Marrow Transplantation.

[37]  A. Petrie,et al.  A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.

[38]  S. Vasanawala,et al.  18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition , 2018, EJNMMI Research.

[39]  Yong-il Kim,et al.  Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis , 2018, Journal of Nuclear Cardiology.

[40]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[41]  P. Hawkins,et al.  Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[42]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[43]  Christophe Leclercq,et al.  2018 ESC Guidelines for the diagnosis and management of syncope , 2018, European heart journal.

[44]  A. Einstein,et al.  Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis , 2018, Journal of Nuclear Cardiology.

[45]  M. Broder,et al.  Epidemiology of AL amyloidosis: a real-world study using US claims data. , 2018, Blood advances.

[46]  John O. Prior,et al.  Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  H. Katus,et al.  Left Ventricular Biopsy in the Diagnosis of Myocardial Diseases. , 2018, Circulation.

[48]  Clarissa M Koch,et al.  Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin , 2018, Circulation. Heart failure.

[49]  D. Forman,et al.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis , 2017, Journal of Cardiovascular Magnetic Resonance.

[50]  A. Thiagalingam,et al.  The value of endomyocardial biopsy in diagnosis and guiding therapy. , 2017, Pathology.

[51]  J. Zamorano,et al.  Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. , 2017, European heart journal cardiovascular Imaging.

[52]  Richard B. Thompson,et al.  Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI) , 2017, Journal of Cardiovascular Magnetic Resonance.

[53]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[54]  D. Judge,et al.  Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[55]  P. Elliott,et al.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis , 2017, Circulation.

[56]  J. Voigt,et al.  Echo Parameters for Differential Diagnosis in Cardiac AmyloidosisCLINICAL PERSPECTIVE , 2017 .

[57]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[58]  J. Moon,et al.  Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic StenosisCLINICAL PERSPECTIVE , 2016 .

[59]  Sanjiv J. Shah,et al.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). , 2016, Journal of the American College of Cardiology.

[60]  Eike Nagel,et al.  T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. , 2016, Circulation research.

[61]  P. Schirmacher,et al.  Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis. , 2016, Journal of the American College of Cardiology.

[62]  R. Hachamovitch,et al.  Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. , 2016, International journal of cardiology.

[63]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[64]  P. Araoz,et al.  LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis. , 2016, JACC. Cardiovascular imaging.

[65]  J. Deux,et al.  Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis. , 2016, JACC Cardiovascular Imaging.

[66]  O. Suhr,et al.  Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry , 2016, Transplantation.

[67]  M. Skinner,et al.  Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study , 2016, Circulation.

[68]  P. Westermark,et al.  99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis , 2016, Upsala journal of medical sciences.

[69]  H. Katus,et al.  Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study , 2015, Drug design, development and therapy.

[70]  Piet Claus,et al.  Tissue Tracking Technology for Assessing Cardiac Mechanics: Principles, Normal Values, and Clinical Applications. , 2015, JACC. Cardiovascular imaging.

[71]  E. Nagel,et al.  T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study. , 2015, Circulation. Cardiovascular imaging.

[72]  J. Dubois-Randé,et al.  Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis , 2015, Orphanet Journal of Rare Diseases.

[73]  G. Merlini,et al.  Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium , 2015, Advances in Therapy.

[74]  P. Kellman,et al.  Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2015, Circulation.

[75]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[76]  J. Dubois-Randé,et al.  Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis , 2015, Orphanet Journal of Rare Diseases.

[77]  N. Heaton,et al.  Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? , 2015, Transplantation.

[78]  P. Hawkins,et al.  A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. , 2015, European heart journal.

[79]  F. Salvi,et al.  Cardiac amyloidosis: the great pretender , 2015, Heart Failure Reviews.

[80]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[81]  P. Hawkins,et al.  Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis , 2014, BMJ Case Reports.

[82]  D. Real de Asúa,et al.  Systemic AA amyloidosis: epidemiology, diagnosis, and management , 2014, Clinical epidemiology.

[83]  R. Falk,et al.  Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. , 2014, JACC. Heart failure.

[84]  R. Falk,et al.  Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[85]  W. Edwards,et al.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.

[86]  B. Hazenberg,et al.  Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[87]  Adelaide M. Arruda-Olson,et al.  Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. , 2014, The American journal of cardiology.

[88]  James A. White,et al.  CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. , 2014, JACC. Cardiovascular imaging.

[89]  S. K. White,et al.  Native T1 mapping in transthyretin amyloidosis. , 2014, JACC. Cardiovascular imaging.

[90]  Lluís Mont,et al.  2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[91]  A. Dispenzieri,et al.  Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis , 2013, Journal of cardiovascular electrophysiology.

[92]  M. Robson,et al.  Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. , 2013, JACC. Cardiovascular imaging.

[93]  B. Lindsay,et al.  ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, Ameri , 2013, Journal of the American College of Cardiology.

[94]  M. Maurer,et al.  99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses , 2013, Circulation. Cardiovascular imaging.

[95]  R. Falk,et al.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis , 2012, Leukemia.

[96]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  B. Fernandez,et al.  AL Amyloidosis , 2012, Orphanet Journal of Rare Diseases.

[98]  R. Falk,et al.  Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). , 2012, American heart journal.

[99]  P. Dreger,et al.  Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis , 2012, Bone Marrow Transplantation.

[100]  James D. Thomas,et al.  Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis , 2012, Heart.

[101]  P. Hawkins,et al.  Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. , 2012, European heart journal.

[102]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  P. Brugada,et al.  Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. , 2012, The American journal of cardiology.

[104]  D. Dingli,et al.  High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. , 2012, Blood.

[105]  P. Hawkins,et al.  Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. , 2011, Blood.

[106]  D. Seldin,et al.  Myocardial infarction with “clean coronaries” caused by amyloid light-chain AL amyloidosis: a case report and literature review , 2011, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[107]  J. Kelly,et al.  Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. , 2011, Biochemical and biophysical research communications.

[108]  Tyler E. Benedum,et al.  Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. , 2011, Seminars in nuclear medicine.

[109]  F. Salvi,et al.  Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. , 2011, JACC. Cardiovascular imaging.

[110]  F. Salvi,et al.  Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[111]  M. Schieber,et al.  Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy: Differences in Complication Rate and Diagnostic Performance , 2010, Circulation.

[112]  MichaelBöhm,et al.  Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy , 2010 .

[113]  F. Salvi,et al.  Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.

[114]  A. Dispenzieri,et al.  Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. , 2010, European heart journal.

[115]  M. Dimopoulos,et al.  Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  Matthew W. Martinez,et al.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. , 2010, JACC. Cardiovascular imaging.

[117]  Y. Ando,et al.  Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[118]  F. Salvi,et al.  Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types , 2009, Circulation.

[119]  G. Merlini,et al.  Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. , 2009, Clinical chemistry.

[120]  C. Rowe,et al.  Radiation Dosimetry of β-Amyloid Tracers 11C-PiB and 18F-BAY94-9172 , 2009, Journal of Nuclear Medicine.

[121]  D. Pennell,et al.  Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[122]  W. Hoffmann,et al.  Complication Rate of Right Ventricular Endomyocardial Biopsy via the Femoral Approach: A Retrospective and Prospective Study Analyzing 3048 Diagnostic Procedures Over an 11-Year Period , 2008, Circulation.

[123]  K. Klingel,et al.  Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. , 2008, Journal of the American College of Cardiology.

[124]  H. Goldschmidt,et al.  Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. , 2008, Heart rhythm.

[125]  M. Leirisalo-Repo,et al.  Amyloidosis is frequently undetected in patients with rheumatoid arthritis , 2008, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[126]  Krishnaswamy Chandrasekaran,et al.  Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis , 2007, Circulation.

[127]  M. Salvadori,et al.  Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[128]  Caroline A Sabin,et al.  Natural history and outcome in systemic AA amyloidosis. , 2007, The New England journal of medicine.

[129]  T. Tokuda,et al.  Progressive Wild‐Type Transthyretin Deposition after Liver Transplantation Preferentially Occurs onto Myocardium in FAP Patients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[130]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[131]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[132]  P. Hawkins,et al.  Liver transplantation in transthyretin-related familial amyloid polyneuropathy , 2004, Current opinion in neurology.

[133]  T. Therneau,et al.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. , 2004, Blood.

[134]  Giampaolo Merlini,et al.  Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.

[135]  S. Yamasaki,et al.  Clinical outcome and survival of secondary (AA) amyloidosis. , 2003, Clinical and experimental rheumatology.

[136]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[137]  D. Booth,et al.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. , 2002, The New England journal of medicine.

[138]  C. Röcken,et al.  Pathology, diagnosis and pathogenesis of AA amyloidosis , 2002, Virchows Archiv.

[139]  G. Palladini,et al.  Holter Monitoring in AL Amyloidosis: Prognostic Implications , 2001, Pacing and clinical electrophysiology : PACE.

[140]  M. Rivera,et al.  Cardiac tamponade as presentation of systemic amyloidosis. , 1992, International journal of cardiology.

[141]  A. Linos,et al.  Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. , 1992, Blood.

[142]  R A Kyle,et al.  Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. , 1983, The American journal of medicine.

[143]  M. Stephens,et al.  Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. , 1982, Thorax.

[144]  P. Raskin,et al.  Increased incidence and clinical correlation of persistently abnormal technetium pyrophosphate myocardial scintigrams following acute myocardial infarction in patients with diabetes mellitus. , 1982, American heart journal.

[145]  Y. Sohn,et al.  Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. , 1982, American heart journal.

[146]  G. Cheon,et al.  11C-Pittsburgh B PET imaging in cardiac amyloidosis. , 2015, JACC. Cardiovascular imaging.

[147]  J. Nielsen,et al.  ESC Guidelines on cardiac pacing and cardiac resynchronization therapy , 2014 .

[148]  S. Schrier,et al.  Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. , 2014, Heart rhythm.

[149]  Jeroen J. Bax,et al.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.

[150]  M. V. van Rijswijk,et al.  Systemic amyloidosis: a clinical survey of 144 cases. , 1986, The Netherlands journal of medicine.